UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

~~Pursuant~~SECTION to13 ~~the~~OR ~~Securities~~15(d) ~~Exchange~~OF ~~Act of 1933~~THE

~~Date~~SECURITIES ofEXCHANGE ~~Report (Date~~ACT ofOF ~~earliest event reported)~~1934

~~April~~Date 24of report (Date of earliest event reported): January 26, ~~2024~~ 2026

THC ~~FARMACEUTICALS~~Farmaceuticals, ~~INC~~Inc.

~~formerly,~~(Exact ~~City~~Name ~~Media,~~of ~~Inc.~~Registrant as Specified in Charter)

(Exact name of registrant as specified in its charter)

Colorado	000-54754	26-1805170
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

~~COLORADO~~1000 Newbury Rd., Suite 290-B, Thousand Oaks, CA 91320

(~~State~~Address orof ~~other~~Principal ~~jurisdiction~~Executive ofOffices) ~~incorporation~~(Zip Code)

~~000~~(323) 420-~~54754~~8583

(~~Commission~~Registrant’s ~~File~~telephone ~~No.~~number, including area code)

~~1000~~Check ~~Newbury~~the ~~Road~~appropriate ,box ~~290~~below if the Form 8-~~unit~~K Bfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~Thousand~~☐ ~~Oaks,~~Written CAcommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.,425) ~~91320~~☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

(Address of principal executive offices and Zip Code)

323-420-8583

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered ~~Common~~common CBDG ~~OTC Markets~~NONE

~~ITEM~~Indicate 8by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.01405) ~~OTHER~~or ~~EVENTS~~Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). ☐

~~Tach~~If ~~LLC~~an ~~entered~~emerging ~~into~~growth acompany, ~~binding~~indicate ~~agreement~~by check mark if the registrant has elected not to use the extended transition period for complying with ~~THC~~any ~~Farmaceuticals,~~new ~~Inc.,~~or ~~which~~revised ~~includes~~financial ~~below~~accounting ~~selected~~standards ~~information~~provided ~~below:~~pursuant to Section 13(a) of the Exchange Act. ☐

Section ~~This~~5 Partnership Agreement is made as of the 22nd day of March 2024 by and between Tach LLC., a Delaware LLC, (“Tach”), THC Farmaceuticals, Inc. a Colorado Corporation with an office address at 1000 Newbury Rd., 290 unit -B, ~~Thousand~~Corporate ~~Oaks,~~Governance ~~California 91320, (“CBDG”)~~ and ~~an LLC member, developer of a certain POS marketing platform dedicated to herbal medicines.~~Management

Item ~~Whereas,~~5.03. ~~Tach~~Amendments ~~and CBDG desire~~ to ~~form~~Articles aof ~~for~~Incorporation ~~profit~~or ~~joint~~Bylaws; ~~venture~~Change ~~partnership on the terms and conditions set forth~~ in ~~this~~Fiscal ~~Agreement~~Year.

On ~~For~~December ~~good~~31, ~~and valuable consideration~~2024, the ~~receipt~~Board ~~and~~of ~~sufficiency~~Directors of ~~which~~THC ~~are~~Farmaceuticals, ~~hereby~~Inc. ~~acknowledged,~~(the “Company”) approved a change in the ~~parties~~Company’s ~~agree~~fiscal ~~follows:~~year end from September 30 to December 31.

1.The ~~Tach,~~Board ~~LLC~~approved ~~(The~~this ~~LLC)~~change ~~was~~to ~~formed~~better ~~for~~align the ~~purpose~~Company’s ofreporting ~~owning~~cycle with the calendar year and ~~further~~to ~~developing~~improve comparability of the ~~POS~~Company’s ~~marketing~~financial ~~platform~~reporting ~~dedicated~~period toand ~~herbal~~planning ~~medicines~~cycle.

2.Following ~~Tach~~this ~~LLC~~change, ~~Interests~~the ~~(units)~~Company’s fiscal year will end on December 31. The ~~LLC~~Company ~~allows~~will ~~for~~file ~~sufficient~~any ~~LLC~~required ~~units~~transition ~~which~~reporting ~~are~~for ~~currently~~the ~~available~~short toperiod ~~issue~~created upby tothis ~~51%~~change ofin ~~same~~fiscal toyear ~~CBDG~~end.

3.No ~~Capitalization.~~amendment ~~The parties each agree~~ to ~~purchase, for their own account, pursuant to section 1244 of~~ the ~~Internal~~Company’s ~~Revenue~~Articles ~~Code~~ of ~~1986,~~Incorporation asor ~~amended,~~Bylaws ~~the~~was ~~number~~required ofin ~~and~~connection ~~type~~with ofthis ~~shares,~~change ~~LLC~~in ~~interest~~fiscal ~~as set forth below:~~ year.

~~CBDG~~Item ~~will~~9.01. ~~purchase~~Financial ~~from~~Statements ~~Tach LLC 51% of all issued~~ and ~~outstanding LLC interests (the "Interests") of TACH by issuing to it 1,000,000 authorized but not yet issued common stock of CBDG~~Exhibits.

~~Tach LLC has already been capitalized an LLC member’s intellectual property for which he~~ (~~and his associates~~d) ~~will own the remaining 49% of Tach LLC upon issuance of 51% of the then issued and outstanding units of LLC interests to CBDG~~Exhibits.

4None. Additional Contributions. For each manager selected to manage the LLC by current LLC members, CBDG will provide an additional co-manager. The LLC’s initial member will cause the LLC within 90 days of this agreement to be a fully operating entity, including a fully functional platform and at least three clients utilizing the services of same with at least one full time salesman trained and equipped to sign up additional clients.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of ~~1933~~1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Dated~~THC ~~this~~FARMACEUTICALS, ~~24th day of April 2024~~INC.

~~THC~~Date: ~~FARMACEUTICALS, INC.~~01/26/2026

BYBy: /Ss/ David Tobias

David Tobias, Executive Director

-2-

Filing Compare · THC Farmaceuticals, Inc.